Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYTK – Cytokinetics, Incorporated

CYTK — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

13.01

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.16

EPS Last/This Y

EPS This/Next Y

1.72

Price

62.5

Target Price

92.78

Analyst Recom

1.33

Performance Q

-2.62

Upside

-465.7%

Beta

0.5

Ticker: CYTK



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-02-27CYTK62.240.230.2094496
2026-03-02CYTK61.460.230.0897681
2026-03-03CYTK60.690.240.1297723
2026-03-04CYTK62.240.230.08100833
2026-03-05CYTK62.20.237.06100644
2026-03-06CYTK60.40.241.40101149
2026-03-09CYTK62.410.240.03101442
2026-03-10CYTK64.240.240.41102724
2026-03-11CYTK63.60.240.05106273
2026-03-12CYTK60.020.242.84110580
2026-03-13CYTK600.242.85110580
2026-03-17CYTK62.160.280.89122620
2026-03-18CYTK62.230.290.36125670
2026-03-19CYTK62.930.302.77126959
2026-03-20CYTK61.690.320.20129882
2026-03-23CYTK60.940.300.70114553
2026-03-24CYTK60.040.300.27116909
2026-03-25CYTK62.370.300.07118466
2026-03-26CYTK63.470.301.11119785
2026-03-27CYTK62.520.300.75121370
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-02-27CYTK62.24-21.9-83.3-6.63
2026-03-02CYTK61.40-18.7-29.0-6.44
2026-03-03CYTK60.68-18.7-29.3-6.44
2026-03-04CYTK62.23-18.7-54.3-6.44
2026-03-05CYTK62.22-18.7-12.1-6.44
2026-03-06CYTK60.39-18.76.8-6.44
2026-03-09CYTK62.40-18.7-34.2-6.44
2026-03-10CYTK64.30-18.7-32.7-6.44
2026-03-11CYTK63.65-18.7-6.6-6.44
2026-03-12CYTK60.01-18.725.0-6.44
2026-03-13CYTK60.08-18.7-13.2-6.44
2026-03-17CYTK62.14-18.7-26.7-6.44
2026-03-18CYTK62.19-18.7-13.3-6.44
2026-03-19CYTK62.93-18.7-76.8-6.44
2026-03-20CYTK61.70-20.2-53.9-6.51
2026-03-23CYTK60.96-20.2-59.8-6.51
2026-03-24CYTK60.04-20.9-57.7-6.54
2026-03-25CYTK62.35-20.9-95.5-6.54
2026-03-26CYTK63.53-20.9-81.4-6.54
2026-03-27CYTK62.50-20.9-57.5-6.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-02-27CYTK-7.35-3.1812.38
2026-03-02CYTK-7.47-2.8312.28
2026-03-03CYTK-7.23-2.8312.28
2026-03-04CYTK-7.23-2.8312.28
2026-03-05CYTK-8.02-2.8312.28
2026-03-06CYTK-8.02-2.8312.28
2026-03-09CYTK-8.02-2.8412.28
2026-03-10CYTK-8.02-2.8412.28
2026-03-11CYTK-8.37-2.8412.77
2026-03-12CYTK-8.37-2.8412.77
2026-03-13CYTK-8.37-2.8412.77
2026-03-17CYTK-8.27-2.8412.77
2026-03-18CYTK-8.33-2.8412.77
2026-03-19CYTK-10.16-2.8412.77
2026-03-20CYTK-10.16-2.8412.77
2026-03-23CYTK-10.16-2.8312.77
2026-03-24CYTK-10.10-2.8312.77
2026-03-25CYTK-10.10-2.8313.01
2026-03-26CYTK-10.10-2.8313.01
2026-03-27CYTK-10.10-2.8313.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-1.5

Avg. EPS Est. Current Quarter

-1.64

Avg. EPS Est. Next Quarter

-1.66

Insider Transactions

-10.1

Institutional Transactions

-2.83

Beta

0.5

Average Sales Estimate Current Quarter

8

Average Sales Estimate Next Quarter

16

Fair Value

Quality Score

9

Growth Score

43

Sentiment Score

95

Actual DrawDown %

43.3

Max Drawdown 5-Year %

-72.4

Target Price

92.78

P/E

Forward P/E

PEG

P/S

87.43

P/B

P/Free Cash Flow

EPS

-6.53

Average EPS Est. Cur. Y​

-6.54

EPS Next Y. (Est.)

-4.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-891.6

Relative Volume

0.89

Return on Equity vs Sector %

91.7

Return on Equity vs Industry %

107.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.46

EBIT Estimation

-57.5
◆ CYTK Healthcare
$62.50
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
8/20
Pullback
17/25
Volume
7/15
Valuation
9/20
TP/AR
4/10
Options
5/10
RSI
49.8
Range 1M
71.4%
Sup Dist
0.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
27 /100
WEAK
Momentum
5/25
Growth
13/30
Estimates
3/20
Inst/Vol
1/15
Options
5/10
EPS Yr
2%
EPS NY
26.8%
52W%
80.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +48.4% upside
Quality
7/30
Valuation
10/30
Growth
9/25
Stability
8/10
LT Trend
2/5
Upside
+48.4%
Quality
9
Click a card to see score breakdown Full Analysis →
Cytokinetics, Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 673
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK

Latest News

—
Caricamento notizie per CYTK…
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading